Jasper Therapeutics (NASDAQ:JSPR) Releases Earnings Results, Beats Estimates By $0.08 EPS

Jasper Therapeutics (NASDAQ:JSPR) issued its quarterly earnings results on Thursday. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.08, Zacks reports.

Jasper Therapeutics Price Performance

Shares of Jasper Therapeutics stock traded up $0.04 during trading on Thursday, reaching $0.96. 180,460 shares of the company traded hands, compared to its average volume of 553,856. Jasper Therapeutics has a 1-year low of $0.62 and a 1-year high of $7.19. The company has a 50 day moving average price of $1.02 and a 200-day moving average price of $1.45. The firm has a market capitalization of $26.85 million, a PE ratio of -0.21 and a beta of 3.07.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Knott David M Jr lifted its position in shares of Jasper Therapeutics by 5.8% during the 4th quarter. Knott David M Jr now owns 181,389 shares of the company’s stock valued at $332,000 after acquiring an additional 10,000 shares during the period. Acadian Asset Management LLC acquired a new position in Jasper Therapeutics during the first quarter worth $46,000. Engineers Gate Manager LP acquired a new position in Jasper Therapeutics during the second quarter worth $78,000. Renaissance Technologies LLC raised its holdings in Jasper Therapeutics by 9.0% during the fourth quarter. Renaissance Technologies LLC now owns 227,183 shares of the company’s stock worth $416,000 after buying an additional 18,683 shares during the last quarter. Finally, Panagora Asset Management Inc. acquired a new position in Jasper Therapeutics during the fourth quarter worth $35,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on JSPR shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Tuesday, April 21st. UBS Group started coverage on shares of Jasper Therapeutics in a research report on Monday, March 23rd. They set a “neutral” rating on the stock. Six investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $19.88.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.